ARCHIVES

FDA Approval Of Two Generic Versions Of Taxol Likely To End BMS Exclusivity.

This article is from The Cancer Letter archive.

Vol. 26 No. 35 | September 29, 2000

Download PDF Visit The Full Archive

Related Articles

Cooperative Group Massacre Hurt Some Of Best CCOPs Which May Go Unfunded

March 27, 1987

Harvard Physician Whose Cancer Was Spread Through Morcellation Seeks to Revamp FDA Regulation of Medical Devices

July 4, 2014

CTEP Director Friedman Adds To Article On Minority Initiative

March 23, 1990

AACI Summarizes Position On New Core Guidelines

May 16, 1980

New Guidelines Developed For Cancer Control Granters For Community Outreach

June 4, 1976

Pursuit Of Truth Was Not An NIH Objective In Gallo Case, Dingell Staff Report Says

January 6, 1995